Search

Your search keyword '"Grennan, Troy"' showing total 423 results
Start Over Author "Grennan, Troy"
423 results on '"Grennan, Troy"'

5. Examining the impacts of a syphilis awareness campaign among gay, bisexual, and other men who have sex with men (gbMSM) in British Columbia, Canada

Author

Sang, Jordan M., Wong, Jason, Ryan, Venessa, Cumming, Emma, Wang, Lu, Cui, Zishan, Bacani, Nicanor, Haag, Devon, Lachowsky, Nathan J., Cox, Joseph, Grace, Daniel, Otterstatter, Michael, Morshed, Muhammad, Edward, Joshua, Grennan, Troy, Arkles, Jillian, Brownrigg, Bobbi, Hogg, Robert S., and Moore, David M.

Published
2023
Full Text
View/download PDF

6. A practical approach to the diagnosis and management of chlamydia and gonorrhea

Author

Van Ommen, Clara E., Malleson, Sarah, and Grennan, Troy

Subjects
Primary health care -- Methods, Gonorrhea -- Diagnosis -- Care and treatment, Chlamydia infections -- Diagnosis -- Care and treatment, Health
Abstract

The 2 most frequent reportable bacterial sexually transmitted infections (STIs) worldwide and in Canada are those caused by Chlamydia trachomatis and Neisseria gonorrhoeae (1,2) Rates of both infections have been [...]

Published
2023
Full Text
View/download PDF

13. Anal cancer screening

Author

Grennan, Troy and Salit, Irving E.

Subjects
Anal cancer -- Diagnosis -- Physiological aspects -- Care and treatment, Cancer -- Diagnosis, Papillomavirus infections -- Diagnosis -- Physiological aspects -- Care and treatment, Health
Abstract

1 Anal cancer disproportionately affects people living with HIV Anal cancer is caused mainly by human papillomavirus (HPV), most commonly HPV-16. It occurs in 1-2 per 100 000 people in [...]

Published
2024
Full Text
View/download PDF

14. Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017–2019.

Author

Alessandrini, Jenna, Cox, Joseph, Pokomandy, Alexandra de, Hart, Trevor A, Grace, Daniel, Grennan, Troy, Moore, David, Lambert, Gilles, Chambers, Catharine, Deeks, Shelley L, Grewal, Ramandip, Lachowsky, Nathan J, Sauvageau, Chantal, Tan, Darrell H S, Coutlée, François, Burchell, Ann N, and Team, the Engage-HPV

Subjects
BISEXUAL men, HUMAN papillomavirus vaccines, HUMAN papillomavirus, VACCINE effectiveness, VACCINATION status
Abstract

Background Oral human papillomavirus (HPV) infections are a leading cause of oropharyngeal cancers. In 2015 and 2016, HPV vaccines became publicly funded for gay, bisexual, and other men who have sex with men (GBM) under 27 years of age in most Canadian provinces. Methods Between 2017 and 2019, sexually active GBM in Montreal, Toronto, and Vancouver were recruited through respondent-driven sampling. Participants aged 16–30 years were invited to self-collect oral rinse specimens for HPV testing. We estimated HPV prevalence in the oral tract overall and compared these by vaccination status. Results Among the 838 GBM with a valid oral specimen, 36.9% reported receiving ≥1 dose of HPV vaccine. Overall, oral HPV prevalence was 2.6% (95% confidence interval [CI], 1.5%–3.7%) for at least 1 HPV type and 1.2% (95% CI,.5%–1.9%) for any high-risk type. We detected quadrivalent (HPV 6/11/16/18) vaccine-preventable types in 0.3% (95% CI,.0%–1.0%) of vaccinated individuals and 1.1% (95% CI,.1%–2.0%) of unvaccinated individuals. Conclusions Oral HPV prevalence was low in a population of young urban GBM in Canada, of whom 37% were vaccinated. Findings serve as a benchmark for monitoring of vaccination impacts on oral HPV infection within this priority population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. COVID‐19 vaccine effectiveness by HIV status and history of injection drug use: a test‐negative analysis

Author

Puyat, Joseph H., Wilton, James, Fowokan, Adeleke, Janjua, Naveed Zafar, Wong, Jason, Grennan, Troy, Chambers, Catharine, Kroch, Abigail, Costiniuk, Cecilia T., Cooper, Curtis L., Lauscher, Darren, Strong, Monte, Burchell, Ann N., Anis, Aslam, and Samji, Hasina

Subjects
Immune response -- Observations, Intravenous drug abuse -- Physiological aspects, HIV infection -- Physiological aspects, Health
Abstract

: Introduction: People living with HIV (PLWH) and/or who inject drugs may experience lower vaccine effectiveness (VE) against SARS‐CoV‐2 infection. Methods: A validated algorithm was applied to population‐based, linked administrative datasets in the British Columbia COVID‐19 Cohort (BCC19C) to ascertain HIV status and create a population of PLWH and matched HIV‐negative individuals. The study population was limited to individuals who received an RT‐PCR laboratory test for SARS‐CoV‐2 between 15 December 2020 and 21 November 2021 in BC, Canada. Any history of injection drug use (IDU) was ascertained using a validated administrative algorithm. We used a test‐negative study design (modified case−control analysis) and multivariable logistic regression to estimate adjusted VE by HIV status and history of IDU. Results: Our analysis included 2700 PLWH and a matched population of 375,043 HIV‐negative individuals, among whom there were 351 and 103,049 SARS‐CoV‐2 cases, respectively. The proportion of people with IDU history was much higher among PLWH compared to HIV‐negative individuals (40.7% vs. 4.3%). Overall VE during the first 6 months after second dose was lower among PLWH with IDU history (65.8%, 95% CI = 43.5–79.3) than PLWH with no IDU history (80.3%, 95% CI = 62.7–89.6), and VE was particularly low at 4–6 months (42.4%, 95% CI = −17.8 to 71.8 with IDU history vs. 64.0%; 95% CI = 15.7–84.7 without), although confidence intervals were wide. In contrast, overall VE was 88.6% (95% CI = 88.2–89.0) in the matched HIV‐negative population with no history of IDU and remained relatively high at 4–6 months after second dose (84.6%, 95% CI = 83.8–85.4). Despite different patterns of vaccine protection by HIV status and IDU history, peak estimates were similar (≥88%) across all populations. Conclusions: PLWH with a history of IDU may experience lower VE against COVID‐19 infection, although findings were limited by a small sample size. The lower VE at 4–6 months may have implications for booster dose prioritization for PLWH and people who inject drugs. The immunocompromising effect of HIV, substance use and/or co‐occurring comorbidities may partly explain these findings., INTRODUCTION People living with HIV (PLWH) and people who inject drugs (PWID) are two populations that often overlap and may experience lower vaccine effectiveness (VE) against COVID‐19 infection. Injection drug [...]

Published
2023
Full Text
View/download PDF

26. Self-reported Human Papillomavirus Vaccination and Vaccine Effectiveness Among Men Who Have Sex with Men: A Quantitative Bias Analysis

Author

Chambers, Catharine, primary, Deeks, Shelley L., primary, Sutradhar, Rinku, primary, Cox, Joseph, primary, De Pokomandy, Alexandra, primary, Grennan, Troy, primary, Hart, Trevor, primary, Lambert, Gilles, primary, Moore, David M., primary, Grace, Daniel, primary, Grewal, Ramandip, primary, Jollimore, Jody, primary, Lachowsky, Nathan J., primary, Mah, Ashley, primary, Nisenbaum, Rosane, primary, Ogilvie, Gina, primary, Sauvageau, Chantal, primary, Tan, Darrell H.S., primary, Yeung, Anna, primary, and Burchell, Ann N., primary

Published
2024
Full Text
View/download PDF

36. Summary of the National Advisory Committee on Sexually Transmitted and Blood-Borne Infections (NAC-STBBI) Statement: Recommendations on Screening for Syphilis in Non-Pregnant Adults and Adolescents.

Author

Begum, Housne, Gadient, Stephan, Bullard, Jared, Gratrix, Jennifer, Grennan, Troy, Hatchette, Todd, and Fleurant-Ceelen, Annie

Subjects
BLOODBORNE infections, MEDICAL screening, SYPHILIS, ADULTS, TEENAGERS
Abstract

Background: Sustained and significant increases in Canadian rates of infectious syphilis prompted the National Advisory Committee on Sexually Transmitted and Blood-Borne Infections (NAC-STBBI) to update the existing screening recommendation for non-pregnant adults and adolescents. Methods: These guidelines were developed following the 2014 World Health Organization Handbook. The research question was: "What is the clinical utility of syphilis screening using risk-based versus population-wide approaches for adolescents and adults?" The evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: The environmental scan included 11 guidelines on syphilis screening published between 2014 and January 2023. Two systematic reviews were identified and included. In the updated literature search from November 6, 2019, to January 17, 2023, there were no published systematic reviews on the effectiveness of risk-based screening or the comparison of risk-based and interval screening; however, one recent randomized control trial in Canada was published. Evidence for outcomes, patient values and preferences, resources, acceptability, equity, cost and cost effectiveness and feasibility were reviewed. Conclusion: This statement provides two screening recommendations for adults and adolescents. Recommendation 1: NAC-STBBI recommends syphilis screening in all sexually active persons with a new or multiple partners and/or upon request of the individual. They also recommend screening every three to six months in individuals with multiple partners. Recommendation 2: NAC-STBBI recommends that targeted "opt-out" screening programs should be considered as frequently as every three months when serving population groups and/or communities experiencing a high prevalence of syphilis (and other STBBI). Both are strong recommendations with moderate certainty of evidence. [ABSTRACT FROM AUTHOR]

Published
2024

41. Avantages du depistage opportuniste des infections transmissibles sexuellement en medecine de soins primaires

Author

Grennan, Troy and Tan, Darrell H.S.

Subjects
Sexually transmitted diseases -- Health aspects -- Care and treatment -- Prevention, Infection, Medical care -- Canada, Health
Abstract

On assiste actuellement a une epidemie mondiale d'infections bacteriennes transmissibles sexuellement (ITS), telles que syphilis, chlamydia et gonorrhee; l'Organisation mondiale de la sante estime a pres d'un million par jour [...]

Published
2021
Full Text
View/download PDF

49. Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia

Author

Gilbert, Mark, primary, Ablona, Aidan, additional, Chang, Hsiu-Ju, additional, Grennan, Troy, additional, Irvine, Michael A., additional, Sarai Racey, C., additional, Salway, Travis, additional, Naus, Monika, additional, Dawar, Meena, additional, and Ogilvie, Gina, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results